Legal Representation
Attorney
Martin J. Beran
USPTO Deadlines
Next Deadline
1432 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2019-06-11)
Due Date
June 11, 2029
Grace Period Ends
December 11, 2029
Application History
24 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 11, 2024 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Oct 12, 2019 | FINV | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Sep 23, 2019 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Sep 23, 2019 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Sep 11, 2019 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Jun 11, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Mar 26, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Mar 26, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Mar 6, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Feb 15, 2019 | ALIE | A | ASSIGNED TO LIE |
| Feb 2, 2019 | RFNT | P | REFUSAL PROCESSED BY IB |
| Feb 1, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jan 23, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jan 22, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jan 22, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jan 12, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Jan 12, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Dec 29, 2018 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Dec 28, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Dec 25, 2018 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Dec 20, 2018 | DOCK | D | ASSIGNED TO EXAMINER |
| Dec 20, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Dec 17, 2018 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Dec 13, 2018 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 042
Medical and scientific research in the field of oncology; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Additional Information
Design Mark
The mark consists of two thick red lines crossing in the shape of an X, with red lines radiating from the center between the top and bottom portions of the X.
Color Claim
The color(s) red is/are claimed as a feature of the mark.
Classification
International Classes
042